Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Numab has raised €74M across 2 funding rounds from 4 investors, most recently a Series C round in Jan 2025. Based in Wadenswil, Switzerland; founded 2011; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-01-09 | Series C | €53M | Cormorant Asset Management,Forbion,HBM Healthcare Investments,Novo Holdings | View deal → |
| 2020-09-03 | Series B | €20M | — | View deal → |
